Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 393Brain Neoplasms 162Glioma 156Gliosarcoma 130Astrocytoma 111Central Nervous System Neoplasms 109Melanoma 75Oligodendroglioma 73Neuroblastoma 44Neoplasms 33Medulloblastoma 33Neoplasm Metastasis 29Recurrence 28Ependymoma 25Sarcoma 23Sarcoma, Ewing 22Rhabdomyosarcoma 18Small Cell Lung Carcinoma 16Lymphoma 16Carcinoma, Non-Small-Cell Lung 16Diffuse Intrinsic Pontine Glioma 15Lung Neoplasms 14Breast Neoplasms 14Ovarian Neoplasms 13Neuroendocrine Tumors 13Choroid Plexus Neoplasms 13Optic Nerve Glioma 11Neuroectodermal Tumors, Primitive 11Spinal Cord Neoplasms 10Rhabdoid Tumor 10

Interventions

Erlotinib Hydrochloride 2Bevacizumab 2spartalizumab 1pamiparib 1atezolizumab 1Temozolomide 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Everolimus 1Disulfides 1Contrast Media 1Botulinum Toxins, Type A 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hereditary leiomyomatosis and renal cell cancer × Temozolomide × Clear all
NCT04603365 2023-05-17

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡